管道问题正加剧合并的紧迫性。 - Suppr

Suppr

超能文献

Pipeline problems are increasing the urge to merge.

作者信息

Frantz Simon

出版信息

Nat Rev Drug Discov. 2006 Dec;5(12):977-9. doi: 10.1038/nrd2206.

DOI:10.1038/nrd2206

PMID:17201023

Abstract

摘要

相似文献

Pipeline problems are increasing the urge to merge.

Nat Rev Drug Discov. 2006 Dec;5(12):977-9. doi: 10.1038/nrd2206.

Study reveals secrets to faster drug development.

Nat Rev Drug Discov. 2006 Nov;5(11):883. doi: 10.1038/nrd2189.

A look on the bright side.

Nat Rev Drug Discov. 2005 Feb;4(2):91. doi: 10.1038/nrd1644.

In search of sustainability: process R&D in light of current pharmaceutical industry challenges.

Drug Discov Today. 2006 Nov;11(21-22):966-74. doi: 10.1016/j.drudis.2006.09.012. Epub 2006 Sep 26.

Millennium mergers bring pipeline.

Nat Biotechnol. 1999 Dec;17(12):1151. doi: 10.1038/70687.

The pitfalls in the development of biologic therapy.

Nat Clin Pract Rheumatol. 2007 Jan;3(1):1. doi: 10.1038/ncprheum0373.

The decreased number of new drug approvals (NDAs) has been a topic of considerable debate over the past decade. Preface.

Adv Pharmacol. 2009;57:xi-ii. doi: 10.1016/S1054-3589(08)57015-3.

Avoiding premature licensing.

Nat Rev Drug Discov. 2006 Dec;5(12):985-6. doi: 10.1038/nrd2203.

Concerns raised over declining antiinfectives R&D.

Nat Biotechnol. 2003 Nov;21(11):1255-6. doi: 10.1038/nbt904.

Plasmodium: drug discovery and development--an industrial perspective.

Exp Parasitol. 1997 Nov;87(3):293-304. doi: 10.1006/expr.1997.4230.

引用本文的文献

Metabolomics: a new frontier in neurodegenerative disease biomarker discovery.

Metabolomics. 2025 May 15;21(3):67. doi: 10.1007/s11306-025-02267-7.

(In)Consistent Performance Feedback and the Locus of Search.

J Manage. 2024 Sep;50(7):2927-2954. doi: 10.1177/01492063231185519. Epub 2023 Jul 27.

A conversation between hyphenated spectroscopic techniques and phytometabolites from medicinal plants.

Anal Sci Adv. 2021 Sep 30;2(11-12):579-593. doi: 10.1002/ansa.202100021. eCollection 2021 Dec.

The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance.

PLoS One. 2017 Feb 23;12(2):e0172488. doi: 10.1371/journal.pone.0172488. eCollection 2017.

Meeting the need for regenerative therapies I: target-based incidence and its relationship to U.S. spending, productivity, and innovation.

Tissue Eng Part B Rev. 2012 Apr;18(2):139-54. doi: 10.1089/ten.TEB.2011.0454. Epub 2012 Jan 16.

Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.

AAPS J. 2010 Jun;12(2):117-29. doi: 10.1208/s12248-009-9164-6. Epub 2010 Jan 15.

Concepts and challenges in quantitative pharmacology and model-based drug development.

AAPS J. 2008 Dec;10(4):552-9. doi: 10.1208/s12248-008-9062-3. Epub 2008 Nov 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Pipeline problems are increasing the urge to merge.

Nat Rev Drug Discov. 2006 Dec;5(12):977-9. doi: 10.1038/nrd2206.

Study reveals secrets to faster drug development.

Nat Rev Drug Discov. 2006 Nov;5(11):883. doi: 10.1038/nrd2189.

A look on the bright side.

Nat Rev Drug Discov. 2005 Feb;4(2):91. doi: 10.1038/nrd1644.

In search of sustainability: process R&D in light of current pharmaceutical industry challenges.

Drug Discov Today. 2006 Nov;11(21-22):966-74. doi: 10.1016/j.drudis.2006.09.012. Epub 2006 Sep 26.

Millennium mergers bring pipeline.

Nat Biotechnol. 1999 Dec;17(12):1151. doi: 10.1038/70687.

The pitfalls in the development of biologic therapy.

Nat Clin Pract Rheumatol. 2007 Jan;3(1):1. doi: 10.1038/ncprheum0373.

The decreased number of new drug approvals (NDAs) has been a topic of considerable debate over the past decade. Preface.

Adv Pharmacol. 2009;57:xi-ii. doi: 10.1016/S1054-3589(08)57015-3.

Avoiding premature licensing.

Nat Rev Drug Discov. 2006 Dec;5(12):985-6. doi: 10.1038/nrd2203.

Concerns raised over declining antiinfectives R&D.

Nat Biotechnol. 2003 Nov;21(11):1255-6. doi: 10.1038/nbt904.

Plasmodium: drug discovery and development--an industrial perspective.

Exp Parasitol. 1997 Nov;87(3):293-304. doi: 10.1006/expr.1997.4230.

引用本文的文献

Metabolomics: a new frontier in neurodegenerative disease biomarker discovery.

Metabolomics. 2025 May 15;21(3):67. doi: 10.1007/s11306-025-02267-7.

(In)Consistent Performance Feedback and the Locus of Search.

J Manage. 2024 Sep;50(7):2927-2954. doi: 10.1177/01492063231185519. Epub 2023 Jul 27.

A conversation between hyphenated spectroscopic techniques and phytometabolites from medicinal plants.

Anal Sci Adv. 2021 Sep 30;2(11-12):579-593. doi: 10.1002/ansa.202100021. eCollection 2021 Dec.

The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance.

PLoS One. 2017 Feb 23;12(2):e0172488. doi: 10.1371/journal.pone.0172488. eCollection 2017.

Meeting the need for regenerative therapies I: target-based incidence and its relationship to U.S. spending, productivity, and innovation.

Tissue Eng Part B Rev. 2012 Apr;18(2):139-54. doi: 10.1089/ten.TEB.2011.0454. Epub 2012 Jan 16.

Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.

AAPS J. 2010 Jun;12(2):117-29. doi: 10.1208/s12248-009-9164-6. Epub 2010 Jan 15.

Concepts and challenges in quantitative pharmacology and model-based drug development.

AAPS J. 2008 Dec;10(4):552-9. doi: 10.1208/s12248-008-9062-3. Epub 2008 Nov 12.